Armodafinil 150 mg/day

DRUG4 trials

Sponsors

Cephalon

Conditions

Chemotherapy Side EffectsExcessive SleepinessFatigueHypopneaObstructive Sleep ApneaShift Work Sleep DisorderSleep Hypopnea

Phase 2

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

TerminatedNCT00825227

CephalonChemotherapy Side Effects, Fatigue

Start: 2008-12-31End: 2010-02-28Updated: 2017-11-17

Phase 3

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

CompletedNCT00078325

CephalonHypopnea, Obstructive Sleep Apnea

Start: 2004-02-29End: 2004-11-30Updated: 2013-07-19

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

CompletedNCT00079677

CephalonObstructive Sleep Apnea, Sleep Hypopnea

Start: 2004-03-31End: 2004-10-31Updated: 2013-07-19

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

CompletedNCT00080288

CephalonExcessive Sleepiness, Shift Work Sleep Disorder

Start: 2004-03-31End: 2004-12-31Updated: 2013-07-19

Related Papers

Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.

2009-11-0175 citations